Targeting of cells involved in the pathogenesis of rheumatoid arthritis

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 8-10

  Panayi, G S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Anti CD4 antibodies; Anti ICAM antibodies; gp39; Inflammatory cascade; Rheumatoid arthritis; T cells; Therapies; Type II collagen

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; COLLAGEN TYPE 2; GAMMA INTERFERON; GLYCOPROTEIN GP 39; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6 RECEPTOR; RECEPTOR ANTIBODY; RHEUMATOID FACTOR; TOXIN;

CELL INTERACTION; CONFERENCE PAPER; HUMAN; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; MACROPHAGE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE ACTIVATION;

ARTHRITIS, RHEUMATOID; HUMANS; T-LYMPHOCYTES;

EID: 0032692362     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Panayi GS. T cell dependent pathways in rheumatoid arthritis. Curr Opin Rheumatol 1997;9:236-40.
2. Verheijden GF, Rijnders AW, Bos E et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
3. Thomas R, Quinn C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J Immunol 1996;156:3074-86.
4. Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND. Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Br J Rheumatol 1996;35:33-7.
5. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol 1994;6:797-807.
6. Gross DM, Steere AC, Huber BT. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 1998;160:1022-8.
7. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Network 1993;4: 15-23.
8. Miltenburg AM, Lacraz S, Welgus HG, Dayer JM. Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal fibroblasts. J Immunol 1995;154:2655-67.
9. Case JP, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL. Transin/stromelysin expression in rheumatoid synovium. A transformation-associated metalloproteinase secreted by phenotypically invasive synoviocytes. Am J Pathol 1989;135:1055-64.
10. Okada Y, Morodomi T, Enghlid JJ et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990;194:721-30.
11. Dechanet J, Merville P, Durand I, Banchereau J, Miossec P. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest 1995; 95:456-63.
12. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175:1135-8.
13. Pitzalis C. The Michael Mason Prize Essay 1996. Role of adhesion mechanisms in the pathogenesis of chronic synovitis. Br J Rheumatol 1996;35:1198-215.
14. Tesser JRP, Wiesenhutter C, Levy R et al. Treatment of rheumatoid arthritis with a primatized anti-CD4 monoclonal antibody, SB-210396 (IDEC-CD9.1). Results of an open label extension study in patients responding to induction therapy. Arthritis Rheum 1997;40:1160.
15. Choy EHS, Connolly DJA, Kingsley GH, Johnson JM, Panayi GS. Effect of a humanised non-depleting anti-CD4 monoclonal antibody (mAb) of synovial fluid (SF) in rheumatoid arthritis. Arthritis Rheum 1997;40:130.
16. Kavanaugh AF, Davis LS, Nichols LA et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37:992-9.
17. Strand V, Lipsky PE, Cannon GW et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1993;36:620-30.
18. Kirkham BW, Thien F, Pelton BK et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348-52.
19. Schulze-Koops H, Davis LS, Haverty P, Wacholtz MC, Lipsky P. Reduction of Th1 cell activity in patients with rheumatoid arthritis after treatment with a non-depleting monoclonal antibody to CD4. Arthritis Rheum 1997; 40:963.
20. Choy EH, Adjaye J, Forrest L, Kingsley GH, Panayi GS. Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. Eur J Immunol 1993;23:2676-81.
21. Nishimoto N et al. Inhibiting IL-6 signal transmission: the treatment of rheumatoid arthritis using immunized anti-IL-6 receptor antibody. Mol Med 1997;34:509-11.
22. Schrohenloher RE, Koopman WJ, Woodworth TG, Moreland LW. Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis. J Rheumatol 1996; 23:1845-8.
23. Moreland LW, Heck WL Jr, Koopman WJ et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of a phase I dose escalation study. J Rheumatol 1996; 23:1353-62.
24. Chen YH, Inobe J, Marks R et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376:177-80.
25. Yonnella PA, Chen YH, Inobe J et al. In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR-transgenic mice. J Immunol 1998;160:4708-18.
26. Sieper J, Kary S, Sorensen H et al. Oral type II collagen treatment in early arthritis. Arthritis Rheum 1996;39:41-51.